Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.
|Grade||Last Price||% Change||Price Change|
ACAD closed up 1.13 percent on Friday, July 21, 2017, on 79 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Aug 3
Trend Table & Recent Alerts
|Weak or Absent||Flat||Up||Up|
|See historical ACAD trend table...|
|Date||Alert Name||Type||% Chg|
|Jul 21||Upside 200 DMA Break||Bullish||0.00%|
|Jul 21||Upper Bollinger Band Walk||Other||0.00%|
|Jul 20||200 DMA Resistance||Bearish||1.13%|
|Jul 20||Stochastic Reached Overbought||Other||1.13%|
|Jul 19||Shooting Star Candlestick||Bearish||4.93%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACAD news...
|52 Week High||40.83|
|52 Week Low||20.68|
|200-Day Moving Average||30.3769|
|50-Day Moving Average||27.826|
|20-Day Moving Average||28.6555|
|10-Day Moving Average||28.64|
|Average True Range||1.1773|
|Chandelier Exit (Long, 3 ATRs)||27.0481|
|Chandelier Exit (Short, 3 ATRs)||29.9419|
|Upper Bollinger Band||30.3545|
|Lower Bollinger Band||26.9565|
|Percent B (%b)||1.02|
|MACD Signal Line||0.1578|